Statement: Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 4/36 (11.11%)   Rectal hemorrhage * 1/36 (2.78%)   Disease progression * 1/36 (2.78%)   Device related infection * 1/36 (2.78%)   Skin infection * 1/36 (2.78%)   Hypotension * 1/36 (2.78%)
Secondary_evidence: Adverse Events 1:   Total: 15/41 (36.59%)   Febrile neutropenia * 0/41 (0.00%)   Diarrhea * 1/41 (2.44%)   Stomach pain * 1/41 (2.44%)   Fever * 2/41 (4.88%)   Cytokine release syndrome * 1/41 (2.44%)   Infection * 1/41 (2.44%)   Skin infection * 2/41 (4.88%)   Urinary tract infection * 1/41 (2.44%)   Coagulopathy * 0/41 (0.00%)   INR increased * 0/41 (0.00%)   Lipase increased * 1/41 (2.44%) Adverse Events 2:   Total: 2/5 (40.00%)   Febrile neutropenia * 1/5 (20.00%)   Diarrhea * 0/5 (0.00%)   Stomach pain * 0/5 (0.00%)   Fever * 0/5 (0.00%)   Cytokine release syndrome * 0/5 (0.00%)   Infection * 0/5 (0.00%)   Skin infection * 0/5 (0.00%)   Urinary tract infection * 0/5 (0.00%)   Coagulopathy * 1/5 (20.00%)   INR increased * 1/5 (20.00%)   Lipase increased * 0/5 (0.00%)